Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | G protein-coupled receptor 35 | Starlite/ChEMBL | No references |
Homo sapiens | cannabinoid receptor 1 (brain) | Starlite/ChEMBL | No references |
Homo sapiens | G protein-coupled receptor 55 | Starlite/ChEMBL | No references |
Homo sapiens | cannabinoid receptor 2 (macrophage) | Starlite/ChEMBL | No references |
Rattus norvegicus | Cannabinoid CB1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | G protein-coupled receptor 18 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | D-amino acid oxidase Aao | 0.1425 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable D-amino acid oxidase Aao | 0.1306 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE D-AMINO ACID OXIDASE AAO | 0.1425 | 1 | 0.5 |
Schistosoma mansoni | d-amino acid oxidase | 0.1425 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | = -5 % | Agonist activity at human GPR35 assessed as induction of beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method relative to zaprinast | ChEMBL. | No reference |
Activity (binding) | = 7 % | Agonist activity at human GPR18 expressed in CHO cells assessed as induction of beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method relative to delta9-THC | ChEMBL. | No reference |
Activity (binding) | = 32 % | Agonist activity at human GPR55 expressed in CHO cells assessed as induction of LPI-induced beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method relative to LPI | ChEMBL. | No reference |
EC50 (binding) | > 10 uM | Agonist activity at human GPR35 assessed as induction of beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method | ChEMBL. | No reference |
IC50 (binding) | > 10 uM | Antagonist activity at human GPR35 assessed as reduction of zaprinast-induced beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method | ChEMBL. | No reference |
IC50 (binding) | > 10 uM | Antagonist activity against human GPR55 expressed in CHO cells assessed as reduction in LPI-induced beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method | ChEMBL. | No reference |
IC50 (binding) | > 10 uM | Antagonist activity against human GPR18 expressed in CHO cells assessed as reduction in delta9-THC-induced beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method | ChEMBL. | No reference |
Inhibition (binding) | = 1 % | Displacement of [3H]CP55,940 from CB1 receptor in rat brain cortical membranes at 10 uM | ChEMBL. | No reference |
Inhibition (binding) | = 5 % | Antagonist activity against human GPR18 expressed in CHO cells assessed as reduction in delta9-THC-induced beta-arrestin recruitment at 10 uM by beta-galactosidase enzyme fragment complementation method | ChEMBL. | No reference |
Inhibition (binding) | = 12 % | Antagonist activity at human GPR35 assessed as reduction of zaprinast-induced beta-arrestin recruitment by beta-galactosidase enzyme fragment complementation method relative to untreated control | ChEMBL. | No reference |
Inhibition (binding) | = 18 % | Displacement of [3H]CP55,940 from human recombinant CB2 receptor expressed in HEK293 cells at 10 uM | ChEMBL. | No reference |
Inhibition (binding) | = 25 % | Antagonist activity against human GPR55 expressed in CHO cells assessed as reduction in LPI-induced beta-arrestin recruitment at 10 uM by beta-galactosidase enzyme fragment complementation method | ChEMBL. | No reference |
Inhibition (binding) | = 40 % | Displacement of [3H]CP55,940 from human recombinant CB1 receptor expressed in CHO-K1 cells at 10 uM | ChEMBL. | No reference |
Ki (binding) | > 10 uM | Displacement of [3H]CP55,940 from CB1 receptor in rat brain cortical membranes | ChEMBL. | No reference |
Ki (binding) | > 10 uM | Displacement of [3H]CP55,940 from human recombinant CB2 receptor expressed in HEK293 cells | ChEMBL. | No reference |
Ki (binding) | > 10 uM | Displacement of [3H]CP55,940 from human recombinant CB1 receptor expressed in CHO-K1 cells | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.